An overview of the pathfinder clinical trials program: Long‐term efficacy and safety of N8‐GP in patients with hemophilia A

N8‐GP (turoctocog alfa pegol, Esperoct(®); Novo Nordisk A/S, Bagsvaerd, Denmark) is a state‐of‐the‐art, extended half‐life factor VIII (FVIII) molecule used for prophylactic and on‐demand treatment of patients with hemophilia A. The pathfinder clinical trial program, which began with the pathfinder1...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsushita, Tadashi, Mangles, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540506/
https://www.ncbi.nlm.nih.gov/pubmed/32558236
http://dx.doi.org/10.1111/jth.14958

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540506/
https://www.ncbi.nlm.nih.gov/pubmed/32558236
http://dx.doi.org/10.1111/jth.14958

Ejemplares similares